Search

Your search keyword '"Teich, Niels"' showing total 473 results
Start Over Author "Teich, Niels"
473 results on '"Teich, Niels"'

10. Treatment of Antibiotic Refractory Chronic Pouchitis With JAK Inhibitors and S1P Receptor Modulators: An ECCO CONFER Multicentre Case Series.

Author

Ribaldone, Davide Giuseppe, Testa, Giulia, Verstockt, Bram, Molnar, Tamas, Savarino, Edoardo, Schmidt, Carsten, Vieujean, Sophie, Teich, Niels, Meianu, Corina, Juillerat, Pascal, Grellier, Nathan, and Lobaton, Triana

Abstract

Background and Aims Data regarding the effectiveness and safety of Janus kinase [JAK] inhibitors and sphingosine-1-phosphate [S1P] receptor modulators in antibiotic refractory chronic pouchitis [CARP] are lacking. Methods This ECCO-CONFER project retrospectively collected data for JAK inhibitor or S1P receptor modulator treatments for CARP with at least 3 months of follow-up. The outcomes included corticosteroid- and antibiotic-free clinical response and remission at 3 and 12 months, and trends in modified pouchitis disease activity index [mPDAI], endoscopic PDAI, C-reactive protein, and calprotectin. Results Seventeen treatments in 15 patients were evaluated. Previous pouchitis treatments included infliximab [5/15], adalimumab [4/15], vedolizumab [9/15], and ustekinumab [5/15]. Pooling data on JAK inhibitors [eight tofacitinib, one filgotinib, and six upadacitinib] after 3 months [T3], steroid- and antibiotic-free clinical response was achieved in 53.3% [8/15], and steroid- and antibiotic-free clinical remission was achieved in 40% [6/15]. Of the patients with at least 12 months of follow-up, steroid- and antibiotic-free clinical response was achieved in 50% [3/6] and remission in one patient [16.7%], endoscopic response in 50% [3/6], and endoscopic remission in 50% [3/6]. Of the two ozanimod treatments at T3, steroid- and antibiotic-free clinical response was achieved in one patient, without remission; both discontinued ozanimod before T12. No side effects were reported. Conclusions Small molecules may represent a suitable option for CARP refractory to multiple biologics, deserving further investigation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Treatment of antibiotic refractory chronic pouchitis with JAK inhibitors and S1P receptor modulators: an ECCO CONFER Multicentre Case Series

Author

Ribaldone, Davide Giuseppe, primary, Testa, Giulia, additional, Verstockt, Bram, additional, Molnar, Tamas, additional, Savarino, Edoardo, additional, Schmidt, Carsten, additional, Vieujean, Sophie, additional, Teich, Niels, additional, Meianu, Corina, additional, Juillerat, Pascal, additional, Grellier, Nathan, additional, and Lobaton, Triana, additional

Published
2023
Full Text
View/download PDF

15. Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naïve Crohn’s Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study

Author

Bokemeyer, Bernd, primary, Plachta-Danielzik, Sandra, additional, di Giuseppe, Romina, additional, Efken, Philipp, additional, Mohl, Wolfgang, additional, Hoffstadt, Martin, additional, Krause, Thomas, additional, Schweitzer, Axel, additional, Schnoy, Elisabeth, additional, Atreya, Raja, additional, Teich, Niels, additional, Trentmann, Leo, additional, Ehehalt, Robert, additional, Hartmann, Petra, additional, and Schreiber, Stefan, additional

Published
2023
Full Text
View/download PDF

16. Use of Intestinal Ultrasound to Monitor Crohn’s Disease Activity

Author

Naumann, Axel, Pelster, Gregor, Spengler, Jörg, Büning, Carsten, Gentz, Enno, Matthes, Harald, Nürnberg, Dieter, Jung, Adelheid, Maul, Jochen, Baumgart, Daniel C., Strobel, Deike, Manok, Gabriele, Breidert, Matthias, Scheurlen, Michael, Stallmach, Andreas, Will, Uwe, Krause, Thomas, Krüger, Rolf-Achim, Teich, Niels, Schiefke, Ingolf, Krummenerl, Annette, Fellermann, Klaus, Kilian, Rüdiger, Kucharzik, Torsten, Maaser, Christian, Helwig, Ulf, Meister, Volker, Mielck, Stefan, Ludwig, Diether, Börner, Norbert, Schanz, Stefan, Kihn, Robert, Hoffmann, Robert Manfred, Lanyi, Barbara, Ehehalt, Robert, Wilborn, Burghard, Dumoulin, Franz Ludwig, Mohl, Wolfgang, Lügering, Andreas, Krummenerl, Thomas, Heidemann, Jan, Pichler, Matthias, Allescher, Hans, Meyer-Hilse, Frank, Franke, Gerd-Rüdiger, Bachmann, Oliver, Fähndrich, Martin, Wittig, Bianca M., Rössler, Alexander, and Rath, Stefan

Published
2017
Full Text
View/download PDF

18. Evaluation of a downstaging, bidirectional version of the Montreal classification of Crohn's disease: Analysis of 5‐year follow‐up data from the prospective BioCrohn study

Author

Bokemeyer, Bernd, primary, Plachta‐Danielzik, Sandra, additional, di Giuseppe, Romina, additional, Helwig, Ulf, additional, Teich, Niels, additional, Schmidt, Carsten, additional, Hartmann, Petra, additional, Sobotzki, Christina, additional, and Schreiber, Stefan, additional

Published
2023
Full Text
View/download PDF

19. Long-Term Sequelae of SARS-CoV-2 Infection in Patients with Inflammatory Bowel Diseases Compared to Relatives with SARS-CoV-2 Infection without Inflammatory Bowel Disease and Inflammatory Bowel Disease Patients without SARS-CoV-2: Results of a Retrospective Case-Control Study

Author

Bierbaum, Benedikt, von Arnim, Ulrike, Schmelz, Renate, Rosania, Rosa, Walldorf, Jens, Bierbaum, Michael, Geißler, Sven, Hänßchen, Markus, Stallmach, Andreas, Reuken, Philipp, and Teich, Niels

Abstract

Introduction:Long-term sequelae following acute SARS-CoV-2 infection appear to be common in patients with inflammatory bowel diseases (IBDs). Methods:We examined the frequency and characteristics of post-COVID-symptoms in patients with IBD (IBD-COVID), comparing them to two control cohorts: infected household members of the IBD-COVID patients without IBD (CONT-COVID) and IBD patients without SARS-COV-2 infection (IBD-no-COVID). A questionnaire for the retrospective documentation of possible post-COVID-19 symptoms was distributed to patients and controls from eight referral centers. Results:The 319 IBD-COVID, 108 CONT-COVID, and the 221 IBD-no-COVID patients were similar in terms of sex, age, and comorbidities. The occurrence and duration of fatigue in the IBD-COVID cohort correlated with IBD activity. Other complaints such as reduced cognitive performance (p< 0.05) and sleeping disorders (p< 0.05) were even more common in IBD-COVID patients. Persistent hematochezia (p< 0.001), abdominal pain (p< 0.005), diarrhea (p< 0.0001), and anal problems (p< 0.01) were more often in the IBD-COVID patients than in the CONT-COVID cohort. Furthermore, typical IBD-associated symptoms persist for a longer period after an infection. Frequency of post-COVID complaints is higher in IBD patients compared to controls. After infection, the number of outpatient consultations increased in IBD-COVID patients (7.8% vs. 10.9%, p= 0.008). Conclusion:Fatigue, cognitive impairment, and sleep disturbances are more prevalent among IBD-COVID than CONT-COVID patients. Furthermore, typical IBD-associated symptoms persist for a longer period after an infection. Frequency of post-COVID complaints is higher in IBD patients compared to controls. Tight control of IBD activity could be a suitable tool to avoid post-COVID problems. Long-term medical problems after acute infection with the corona virus SARS-CoV-2 are often complained by patients with inflammatory bowel diseases. The illness caused by SARS-CoV-2 is called COVID-19. Previous studies had usually no control groups. It was therefore not clear, whether problems such as tiredness came from COVID-19 infection or bowel inflammation The objective of our study was to thoroughly examine both COVID-19 and post-COVID-19 symptoms in a cohort from eight clinics. We examined 319 patients with inflammatory bowel disease and COVID-19, 108 patients with inflammatory bowel disease but no COVID-19 and 221 patients with COVID-19 but no inflammatory bowel disease. These groups were similar in terms of sex, age and other characteristics. We found that fatigue, cognitive impairment and sleep disturbances were more prevalent among patients with inflammatory bowel disease and COVID-19. Furthermore, bowel symptoms persist for a longer period after COVOD-19. Frequency of any complaint after COVID-19 s is higher in patients with inflammatory bowel disease compared to controls. Deriving from these results we suggest that tight control of IBD activity could be a suitable tool to avoid long term problems after COVID-19.

Published
2024
Full Text
View/download PDF

21. Real-world Comparative Effectiveness of Ustekinumab vs Anti-TNF in Crohn's Disease With Propensity Score Adjustment: Induction Phase Results From the Prospective, Observational RUN-CD Study.

Author

Bokemeyer, Bernd, Plachta-Danielzik, Sandra, Giuseppe, Romina di, Mohl, Wolfgang, Teich, Niels, Hoffstadt, Martin, Schweitzer, Axel, von der Ohe, Manfred, Gauss, Annika, Atreya, Raja, Krause, Thomas, Blumenstein, Irina, Hartmann, Petra, and Schreiber, Stefan

Published
2023
Full Text
View/download PDF

27. Surgery due to Inflammatory Bowel Disease During Pregnancy: Mothers and Offspring Outcomes From an ECCO Confer Multicentre Case Series [Scar Study]

Author

Chaparro, Maria, Kunovsky, Lumir, Aguas, Mariam, Livne, Moran, Riviere, Pauline, Shitrit, Ariella Bar-Gil, Myrelid, Pär, Arroyo, Maite, Barreiro-de Acosta, Manuel, Bautista, Michelle, Biancone, Livia, Biron, Irit Avni, Boysen, Trine, Carpio, Daniel, Castro, Beatriz, Dragoni, Gabriele, Ellul, Pierre, Holubar, Stefan D., Angel de Jorge, Miguel, Leo, Eduardo, Mancenido, Noemi, Moens, Annick, Molnar, Tamas, Ramirez de la Piscina, Patricia, Ricanek, Petr, Sebkova, Ladislava, Sempere, Laura, Teich, Niels, Gisbert, Javier P., Julsgaard, Mette, Chaparro, Maria, Kunovsky, Lumir, Aguas, Mariam, Livne, Moran, Riviere, Pauline, Shitrit, Ariella Bar-Gil, Myrelid, Pär, Arroyo, Maite, Barreiro-de Acosta, Manuel, Bautista, Michelle, Biancone, Livia, Biron, Irit Avni, Boysen, Trine, Carpio, Daniel, Castro, Beatriz, Dragoni, Gabriele, Ellul, Pierre, Holubar, Stefan D., Angel de Jorge, Miguel, Leo, Eduardo, Mancenido, Noemi, Moens, Annick, Molnar, Tamas, Ramirez de la Piscina, Patricia, Ricanek, Petr, Sebkova, Ladislava, Sempere, Laura, Teich, Niels, Gisbert, Javier P., and Julsgaard, Mette

Abstract

Aims: i] To evaluate the evolution of pregnancies and offspring after inflammatory bowel disease [IBD] surgery during pregnancy; and ii] to describe the indications, the surgical techniques, and the frequency of caesarean section concomitant with surgery. Methods: Patients operated on due to IBD during pregnancy after 1998 were included. Participating clinicians were asked to review their databases to identify cases. Data on patients demographics, IBD characteristics, medical treatments, IBD activity, pregnancy outcomes, surgery, delivery, and foetal and maternal outcomes, were recorded. Results: In all, 44 IBD patients were included, of whom 75% had Crohns disease; 18% of the surgeries were performed in the first trimester, 55% in the second, and 27% in the third trimester. One patient had complications during surgery, and 27% had postsurgical complications. No patient died. Of deliveries, 70% were carried out by caesarean section. There were 40 newborns alive. There were four miscarriages/stillbirths [one in the first, two in the second, and one in the third trimester]; two occurred during surgery, and another two occurred 2 weeks after surgery; 14% of the surgeries during the second trimester and 64% of those in the third trimester ended up with a simultaneous caesarean section or vaginal delivery. Of the 40 newborns, 61% were premature and 47% had low birth weight; 42% of newborns needed hospitalisation [25% in the intensive care unit]. Conclusions: IBD surgery during pregnancy remains an extremely serious situation. Therefore, surgical management should be performed in a multidisciplinary team, involving gastroenterologists, colorectal surgeons, obstetricians, and neonatal specialists.

Published
2022
Full Text
View/download PDF

28. Hereditary Colorectal Cancer Syndromes and Inflammatory Bowel Diseases: an ECCO CONFER Multicentre Case Series

Author

Barberio, Brigida, primary, Savarino, Edoardo, additional, Verstockt, Bram, additional, Fumery, Mathurin, additional, Pugliese, Daniela, additional, Bertani, Lorenzo, additional, Buda, Andrea, additional, Dragoni, Gabriele, additional, Goren, Idan, additional, Laish, Ido, additional, Spinelli, Antonino, additional, Teich, Niels, additional, Truyens, Marie, additional, and Ellul, Pierre, additional

Published
2022
Full Text
View/download PDF

30. Su1515: EFFECT OF VEDOLIZUMAB ON HEALTH-RELATED QUALITY OF LIFE AND 1-YEAR EFFECTIVENESS IN COMPARISON TO ANTI-TNF THERAPY IN BIOLOGIC-NAÏVE CROHN'S DISEASE PATIENTS WITH PROPENSITY SCORE ADJUSTMENT: RESULTS OF THE VEDOIBD STUDY

Author

Giuseppe, Romina di, primary, Plachta-Danielzik, Sandra, additional, Bokemeyer, Bernd, additional, Efken, Philipp, additional, Mohl, Wolfgang, additional, Hoffstadt, Martin, additional, Krause, Thomas, additional, Schweitzer, Axel, additional, Schnoy, Elisabeth, additional, Atreya, Raja, additional, Teich, Niels, additional, Trentmann, Leo, additional, Ehehalt, Robert, additional, Franzenburg, Sina, additional, Hartmann, Petra, additional, and Schreiber, Stefan, additional

Published
2022
Full Text
View/download PDF

31. Mo1544: REAL WORLD EVIDENCE ON QUALITY OF LIFE AND COMPARATIVE EFFECTIVENESS OF USTEKINUMAB VS ANTI-TNF IN CROHN’S DISEASE WITH PROPENSITY SCORE ADJUSTMENT: MAINTENANCE PHASE RESULTS FROM THE PROSPECTIVE OBSERVATIONAL RUN-CD STUDY

Author

Bokemeyer, Bernd, primary, Plachta-Danielzik, Sandra, additional, Giuseppe, Romina di, additional, Deppe, Herbert, additional, Mohl, Wolfgang, additional, Teich, Niels, additional, Hoffstadt, Martin, additional, Schweitzer, Axel, additional, Ohe, Manfred von der, additional, Gauss, Annika, additional, Atreya, Raja, additional, Krause, Thomas, additional, Blumenstein, Irina, additional, Hoechstoedter, Jessica, additional, Hartmann, Petra, additional, and Schreiber, Stefan, additional

Published
2022
Full Text
View/download PDF

32. Surgery due to Inflammatory Bowel Disease During Pregnancy: Mothers and Offspring Outcomes From an ECCO Confer Multicentre Case Series [Scar Study]

Author

Chaparro, María, primary, Kunovský, Lumír, additional, Aguas, Mariam, additional, Livne, Moran, additional, Rivière, Pauline, additional, Bar-Gil Shitrit, Ariella, additional, Myrelid, Pär, additional, Arroyo, Maite, additional, Barreiro-de Acosta, Manuel, additional, Bautista, Michelle, additional, Biancone, Livia, additional, Biron, Irit Avni, additional, Boysen, Trine, additional, Carpio, Daniel, additional, Castro, Beatriz, additional, Dragoni, Gabriele, additional, Ellul, Pierre, additional, Holubar, Stefan D, additional, de Jorge, Miguel Ángel, additional, Leo, Eduardo, additional, Manceñido, Noemí, additional, Moens, Annick, additional, Molnár, Tamás, additional, Ramírez de la Piscina, Patricia, additional, Ricanek, Petr, additional, Sebkova, Ladislava, additional, Sempere, Laura, additional, Teich, Niels, additional, Gisbert, Javier P, additional, and Julsgaard, Mette, additional

Published
2022
Full Text
View/download PDF

33. 1178 PROMISING EFFICACY OF SMALL MOLECULES AND BIOLOGICALS FOR MICROSCOPIC COLITIS: RESULTS FROM A LARGE REAL-LIFE MULTICENTER COHORT

Author

Verstockt, Bram, Taelman, Thibault, Vavricka, Stephan R., Zabana, Yamile, Lenfant, Matthias, Macaigne, Gilles, Maillard, Michel H., Savarino, Edoardo, Teich, Niels, Kiudelis, Vytautas, De La Revilla Negro, Juan, Ribaldone, Davide Giuseppe, Barreiro-De-Acosta, Manuel, Wildt, Signe, Rivière, Pauline, Fumery, Mathurin, Truyens, Marie, Amiot, Aurelien, Marsal, Jan, Levartovsky, Asaf, Vieujean, Sophie, Somers, Michaël, Cremer, Anneline, Lyutakov, Ivan, Cohen, Nathaniel A., De Wit, Sophie, Bajer, Lukas, Rahier, Jean-Francois, Backman, Ann-Sofie, Nancey, Stephane, Choden, Tenzin, Van Dongen, Jurgen, Munch, Andreas, and Julsgaard, Mette

Published
2024
Full Text
View/download PDF

37. Early MOnitoring of REsponse (MORE) to Golimumab Therapy: Results of a Multicentre, Prospective Observational Trial.

Author

Helwig, Ulf, Krause, Thomas Helmut, Maaser, Christian, Büning, Jürgen, Drabik, Attyla, Blömacher, Margit, Plachta-Danielzik, Sandra, Teich, Niels, Krummenerl, Annette, Sturm, Andreas, Schwab, Matthias, and Schreiber, Stefan

Subjects
GOLIMUMAB, ULCERATIVE colitis, BIOTHERAPY, MISSING data (Statistics), CALPROTECTIN, DISEASE remission
Abstract

Background: The therapeutic goal of clinical remission in patients with moderate to severe ulcerative colitis (UC) is achieved after biological therapy only in 16–39%. Individualization of therapeutic intervention would benefit from prediction of early response. Study Objective: The primary objective of our study was to assess golimumab (GLM) trough serum level of ≥2.5 μg/mL in combination with a reduction of faecal calprotectin (FC) of ≥50% at week 6 compared to baseline to predict clinical response at week 26 after regular GLM intake. Methods: Patients with moderate to severe active UC and planned GLM treatment were recruited for a prospective, multicentre, observational study in Germany. Prediction of clinical response was assessed by FC and GLM trough level. Missing data were imputed as therapy failure according to the last observation carried forward method. Results: Fifty nine patients have been enrolled. 54% of patients were anti-TNF naïve. Clinical response at week 6 was a significant predictor for achieving clinical response at week 26 (odds ratio [OR] 10.97, confidence interval [CI], 2.96–40.68; p < 0.001). Moreover, patients with a GLM trough level of ≥2.5 μg/mL and a ≥50% reduction of FC at week 6 had an OR of 5.33 (95% CI, 0.59–47.84) to achieve clinical response at week 26. Conclusion: Clinical response at week 6 is the best predictive marker for achieving clinical response at week 26. Consideration of significant reduction of FC and trough GLM serum levels could improve prediction of response. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

41. Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case Series

Author

Festa, Stefano, primary, Zerboni, Giulia, additional, Derikx, Lauranne A A P, additional, Ribaldone, Davide Giuseppe, additional, Dragoni, Gabriele, additional, Buskens, Christianne, additional, van Dijkum, Els Nieveen, additional, Pugliese, Daniela, additional, Panzuto, Francesco, additional, Krela-Kaźmierczak, Iwona, additional, Mintz, Hilla Reiss, additional, Shitrit, Ariella Bar-Gil, additional, Chaparro, Marìa, additional, Gisbert, Javier P, additional, Kopylov, Uri, additional, Teich, Niels, additional, Vainer, Elez, additional, Nagtegaal, Iris, additional, Hoentjen, Frank, additional, Garcia, Maria Jose, additional, Filip, Rafal, additional, Foteinogiannopoulou, Kalliopi, additional, Koutroubakis, Ioannis E, additional, Argollo, Marjorie, additional, van Wanrooij, Roy L J, additional, Laja, Hendrik, additional, Lobaton, Triana, additional, Truyens, Marie, additional, Molnar, Tamas, additional, Savarino, Edoardo, additional, Aratari, Annalisa, additional, Papi, Claudio, additional, and Goren, Idan, additional

Published
2021
Full Text
View/download PDF

49. 526 PROPENSITY SCORE ADJUSTED QUALITY OF LIFE AND EFFECTIVENESS OF USTEKINUMAB INDUCTION THERAPY IN CROHN'S DISEASE: RESULTS OF THE RUN-CD STUDY

Author

Bokemeyer, Bernd, primary, Plachta-Danielzik, Sandra, additional, di Giuseppe, Romina, additional, Mohl, Wolfgang, additional, Teich, Niels, additional, Hoffstadt, Martin, additional, Schweitzer, Axel, additional, von der Ohe, Manfred, additional, Gauss, Annika, additional, Atreya, Raja, additional, Krause, Thomas, additional, Blumenstein, Irina, additional, Hoechstoedter, Jessica, additional, Hartmann, Petra, additional, and Schreiber, Stefan, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results